This article is available online at http://www.jlr.org Autotaxin (ATX) is a secreted enzyme, which converts extracellular lysophosphatidylcholine (LPC) into lysophosphatidate (LPA). This is an important reaction in cell signaling because LPA activates at least six G proteincoupled receptors to increase cell division, survival, and migration ( 1, 2 ). ATX serves an essential function in embryonic development because ATX knockout mice die in utero at day 9.5 with defects in vasculogenesis and the development of the neural crest ( 3-6 ). In the postnatal organism, the major function of ATX appears to be in wound healing. ATX is produced in response to infl ammation to mediate wound repair. If the infl ammation is not resolved, then high ATX concentrations persist in association with infl ammatory diseases such as arthritis and infl ammatory bowel disease ( 1, 7, 8 ) . In addition, infl ammatory bowel disease and hepatitis can progress to carcinogenesis in these organs ( 1 ). Signifi cantly, increased ATX activity is associated with the growth of breast tumors ( 9, 10 ) and the ATX gene is among the top 40 most upregulated in metastatic cancer ( 11 ). Blocking LPA production by inhibiting ATX activity with ONO-8430506 decreases the fi rst phase of breast tumor growth and subsequent metastasis by about 60 % in mice ( 9, 12 ). Conversely, increasing the low lipid phosphate phosphatase (LPP)1 activity in cancer cells so as to increase LPA turnover in the tumor and attenuate LPA signaling decreased breast tumor growth and metastasis in mice by about 80% ( 13 ). These studies emphasize the importance of ATX in controlling cell signaling in several physiological and pathological conditions. Consequently, it is important to understand how ATX activity and signaling by LPA are regulated. The present work focuses on the role of ATX and how its expression is controlled.
Cell culture
SW-579 (HTB-107™) thyroid cancer cells and MDA-MB-435S (HTB-129™) melanoma cells were purchased from ATCC (Manassas, VA), and cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C, 5% CO 2 , and 95% humidity. Cells were used at low passage number. For all experiments, cells were seeded in 6-well plates and grown until 80% confl uent. Cells were then washed with HEPES buffer saline, and 2 ml RMPI 1640 medium containing either 10% FBS or FBSC with reagents was added for 24 h for RNA experiments or 48 h for ATX ELISA experiments. In some experiments, cells were pretreated in 10% FBS with 1 M wortmannin, 10 M LY294002, 10 M Gö6983, or 20 M PD98059 for 6 h before addition of LPA or S1P to fresh medium with inhibitors. In experiments with 100 M LPC, medium was supplemented with 1% BSA. TNF-␣ and IL-1 ␤ were used at a fi nal concentration of 10 ng/ml.
ATX activity assays
For FS-3 assay measurements, FS-3 substrate was prepared at 1.25 times the fi nal working concentration in FS-3 assay buffer [140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 50 mM Tris-HCl (pH 8.0), and 1 mg/ml BSA]. LPA, S1P, and recombinant ATX were prepared at 10 times the fi nal working concentration in FS-3 assay buffer. FS-3 substrate (80 l) was added to 10 l of ATX protein and 10 l of either C18:1-LPA, S1P, C18:1-LPC, or FS-3 assay buffer for a fi nal volume of 100 l. Final ATX protein concentrations of 75, 100, and 125 ng/ml were used to demonstrate that the activity results were directly proportional to enzyme quantity. Measurements were taken at 5 min intervals for 4 h at 37°C and the kinetics analyzed as previously described ( 32 ) . For ATX inhibition experiments, 0.25-10 l of mouse plasma, FBS, or FBSC was added to 10 l of 100 nM of ONO-8430506 (fi nal concentration 10 nM) and 80 l of 6.25 M FS-3 substrate (fi nal concentration 5 M). To account for slight dilutions of FBSC during the delipidation process, initial rates were normalized to total serum protein as measured by the BCA protein assay (Thermo Fisher Scientifi c, Rockford, IL).
For the choline release method, 10 l of ATX protein was incubated with 25 l of 400 M C18:1-LPC and 15 l of C18:1-LPA or S1P or choline-assay buffer for a total volume of 50 l for 4 h at 37°C. All assay conditions and buffers have been previously described ( 9 ) . Final ATX concentrations of 750, 1,000, and 1,250 ng/ml were used to demonstrate that the activity results were directly proportional to protein. ATX activity in mouse plasma was also assessed using 3 mM C18:1-LPC in the cholinerelease assay as previously described ( 9 ) .
Animal studies and measurement of LPA and S1P concentrations
Female Balb/c mice 8-10 weeks old (BALB/cAnNCrl, Strain Code 028) were from Charles River (Kingston, ON, Canada) and were housed and maintained as previously described ( 9 ) . All procedures were performed in accordance with the Canadian Council of Animal Care as approved by the University of Alberta Animal Welfare Committee. ONO-8430506 was prepared at 10 mg/ml in 25 mM sodium hydroxide and heated to 60°C for 5 min to dissolve ( 9, 29 ) . The solution was passed through a 0.22 m fi lter prior to administration. Mice were then gavaged with water or 100 mg/kg ONO-8430506 (10 l/g body weight) once a day for 4 days. Mice were euthanized at 6 h after the last treatment and tissues were processed as previously described ( 9 ) . For tumor experiments, mice were either sham injected or injected with 20,000 4T1 Balb/c breast cancer cells into the fourth inguinal fat pad and were euthanized 21 days later as previously LPA turns over with a half-life of about 3 min in the circulation ( 14, 15 ) . Steady-state LPA concentrations are regulated partly by the balance of ATX activity versus LPA degradation by the ecto-activities of a family of three LPPs ( 16, 17 ) . Consequently, knocking down LPP1 expression in mice increased the half-life on LPA ( 14 ) . One hypothesis for the regulation of the concentrations of extracellular LPA is that ATX activity is controlled by a product feedback inhibition from LPA or its sphingolipid analog, sphingosine 1-phosphate (S1P). This work is based mainly on studies where ATX activity was measured with very low concentrations (1-5 M) of fl uorescent LPC-analog substrates ( 18, 19 ) . This technique was also used to identify LPA analogs as possible ATX inhibitors (20) (21) (22) (23) .
We questioned whether the inhibition of ATX with LPA and S1P could have physiological relevance because these inhibitions are competitive with the substrate concentration ( 1 ). Circulating LPC concentrations in mice and human beings are in the range of 200-400 M ( 2, 24 ) . These concentrations are very high compared with those of fl uorescent substrates used in the ATX assay ( 1, 25 ) . Our work demonstrates that LPA and S1P produce very little inhibition of ATX activity in assays where the substrate for ATX is raised to the physiological concentrations. However, we did show that ATX activity is regulated by feedback from LPA and S1P, but that this depends on the production of ATX in cancer cells and adipose tissue. This feedback regulation controls the mRNA concentrations for ATX and ATX secretion rather than a direct effect on ATX activity. This level of feedback regulation is overcome by infl ammatory cytokines, which explains why ATX activity and LPA concentrations can be increased in infl ammation and cancer.
MATERIALS AND METHODS

Reagents
C18:1-LPA, C18:1-LPC, and VPC23019 were purchased from Avanti Polar Lipids (Alabaster, AL). Fluorescent substrate-3 (FS-3) fl uorogenic ATX substrate (L-2000) was purchased from Echelon (Salt Lake City, UT). FBS was from Gibco/Life Technologies (Burlington, ON, Canada). FBS was charcoal-treated (FBSC) to remove lipids by adding activated charcoal washed twice with phosphate-buffered saline (2 g per 50 ml of FBS) and then rotated overnight at 4°C. The mixture was then centrifuged and the supernatant was fi ltered twice through 0.22 m sterile fi lters. Ki16425, SEW2871, and human recombinant ATX were from Cayman Chemical (Ann Arbor, MI). LY294002, wortmannin, PD98059, and Gö6983 were purchased from Calbiochem/EMD Millipore (Etobicoke, ON, Canada). Wls-31 was a gift from Dr. W. Santos and Mr. N. Patwardhan (Department of Chemistry, Virginia Polytechnic Institute, VA) ( 26, 27 ) . TNF-␣ and interleukin 1 ␤ (IL-1 ␤ ) were from PeproTech (Rocky Hill, NJ). ONO-8430506 was obtained from Ono Pharmaceuticals (Osaka, Japan; patent number WO2012005227) ( 28, 29 ) under a materials transfer agreement. S32826 was from Institut de Recherches Servier (Croissy-sur-Seine, France) ( 30 ) . Anti-ATX antibody was a gift from Dr. T. Clair (National Cancer Institute, Bethesda, MD) ( 31 ) . Other reagents were from Sigma-Aldrich (Oakville, ON, Canada) unless otherwise indicated. ( Fig. 1A ) .
We also demonstrated that the FS-3 assay does not provide accurate measurements of ATX activity in biological samples if lysophospholipids are present. First, we defi ned ATX activity as the component of the FS-3 measurement that is suppressed by the ATX inhibitor ONO-8430506, as we did previously for the choline release assay ( 9 ) . Using recombinant ATX, 10 nM ONO-8430506 suppressed >97% of the total measured activity ( Fig. 2A ). However, in described ( 9 ) . Plasma concentrations of LPA and S1P were measured by mass spectrometry as previously described ( 9 ) .
Quantitative real-time PCR, Western blotting, and ELISA
Total RNA was extracted from cell lysates using the RNAquesous® kit (Ambion, Streetville, ON, Canada) or from mouse adipose tissue homogenized in Trizol® (Invitrogen Life Technologies, Carlsbad, CA) using the Direct-zol™ RNA MiniPrep kit (R2052; Zymo Research, Irvine, CA) according the manufacturer's instructions. Extracted RNA was treated with DNAase and reverse transcription and quantitative RT-PCR was then performed ( 32 ) . Gene expression was normalized to the housekeeping genes cyclophilin A ( PPIA ) or GAPDH . Relative changes in expression of ATX ( ENPP2 ) mRNA were essentially the same with both reference mRNAs and results are routinely expressed relative to GAPDH mRNA. Primers purchased from Integrated DNA Technologies (Coralville, IA) that recognize both human and mouse transcripts were ATX ( ENPP2 ): sense, 5 ′ -CAT TTA TTG GTG GAA CGC AGA-3 ′ and antisense, 5 ′ -CTA CAA AAA CAG TCT GCA TGC-3 ′ ; and GAPDH : sense, 5 ′ -ACT TTG TCA AGC TCA TTT CC-3 ′ and antisense, 5 ′ -TCT TAC TCC TTG GAG GCC AT-3 ′ . ATX protein in mouse plasma was analyzed by Western blotting as previously described and quantifi ed by ImageJ analysis ( 9 ) . ATX protein concentration was quantifi ed from 100 l of centrifuged cell culture conditioned medium using the ATX sandwich ELISA kit (K-5600) from Echelon according to the manufacturer's instructions. Secreted ATX protein was then normalized to both the incubation volume of conditioned medium and protein content from cell lysates by the BCA protein assay. Mouse plasma TNF-␣ concentrations were measured by Eve Technologies Corporation (Calgary, AB, Canada) using the Luminex™ 100 system (Luminex, Austin, TX).
Statistical analysis
Results are expressed as the mean ± SEM from at least three independent experiments. The two-tailed Student's t -test for comparing two groups or the one-way ANOVA with a Bonferonni post hoc test for three or more groups were used to test for signifi cance. P < 0.05 was used for signifi cance. Statistics were calculated and results plotted using Origin Pro 9.1 (OriginLab Corporation, Northampton, MA).
RESULTS
LPA and S1P have little inhibitory effect on ATX activity at physiological concentrations of substrate concentrations
The hypothesis that LPA and S1P exert feedback regulation on ATX activity was developed mainly by using FS-3, which is an analog of LPC that yields a fl uorescent product when cleaved by ATX ( 19, 33 ) . This compound is relatively expensive and assays are normally performed at low micromolar concentrations of FS-3 ( K m 4.5-6.3 M) ( 19, 33 ) . We used 5 M FS-3 in the assay with recombinant ATX and demonstrated that the reaction was inhibited by increasing LPA and S1P concentrations ( Fig. 1A ) . These inhibitions were progressively decreased when the concentration of FS-3 was increased to 15 and 50 M ( Fig. 1B ) as expected from the mixed-type nature of the inhibition previously described ( 18, 19 ) . C18:1-LPA and S1P had only marginal effects on ATX activity when this was measured using a choline release assay and a Supplemental Material can be found at: Fig. 2 . ATX activity cannot be measured by the FS-3 assay in biological samples if lysophospholipids are present. A: Recombinant ATX (75, 100, and 125 ng/ml) was incubated with or without 10 nM of ONO-8430506 using 5 M of FS-3. ONO-8430506 suppressed >97% of the total activity measured in the assay. B: The same experiment in (A) was conducted using 0.25-10 l of plasma from three different mice (fi nal assay volume of 100 l). ONO-8430506 could not suppress the measured activity and is therefore not from ATX activity. C: LPC potently inhibits ATX activity (ATX at 100 ng/ml concentration) when incubated with FS-3. D: Removing lipids from FBS reveals a component of the measured total activity that can be suppressed by ONO-8430506. These results are obtained from the subtraction of the total measured activity from the activity remaining after adding 10 nM ONO-8430506 (see supplementary Fig. 1 ). All results are mean ± SEM from three independent experiments. plasma, the apparent activity measurements were not suppressed by ONO-8430506, and therefore cannot be attributable to ATX ( Fig. 2B ). Plasma and serum also contain >200 M LPC in addition to LPA and S1P. LPC potently suppressed recombinant ATX activity measurements in the FS-3 assay (IC 50 = 2.5 M) ( Fig. 2C ) . We, therefore, delipidated FBS to see whether this would eliminate the inhibition by lysophospholipids and this increased the ONO-8430506-inhibited activity by nearly 20-fold ( Fig. 2D ,  supplementary Fig. 1 ).
LPA and S1P cause feedback regulation on ATX expression in cultured thyroid cancer and melanoma cells
The concept that LPA exerts a feedback regulation on ATX is an attractive hypothesis and we tested whether this occurred at the level of ATX synthesis. We, therefore, used SW-579 thyroid cancer cells and MDA-MB-435S melanoma cells, which express very high amounts of ATX, to test this hypothesis. Addition of LPA or S1P to medium containing delipidated serum (FBSC) decreased ATX mRNA expression ( Fig. 3A, B ) . We also verifi ed this effect of LPA and S1P on ATX protein secretion by ELISA measurements ( Fig. 3C ) . Incubation with medium containing delipidated serum increased mRNA concentrations for ATX compared with incubation in normal serum ( Fig. 4A , supplementary Fig. 2 ). ATX mRNA expression was suppressed by adding 5 M LPA or S1P to the delipidated medium and these effects were reversed by 1 M Ki16425, a LPA receptor types 1/3 (LPA 1/3 ) antagonist ( 34 ) , and by 1 M VPC23019, a S1P receptor types 1/3 (S1P 1/3 ) antagonist ( 35 ), respectively ( Fig. 4B , supplementary Fig. 2 ). Decreases in ATX mRNA expression were also obtained when the delipidated medium was supplemented with 1 M wls-31 ( 26 ), a LPA 1/2 receptor agonist, or SEW2871, a S1P 1 receptor agonist ( 36 ) ( Fig. 4A , supplementary Fig. 2 ). These results establish that LPA and S1P signaling negatively regulate the expression of ATX.
The effects of LPA and S1P in decreasing mRNA for ATX were blocked by two inhibitors of phosphatidylinositol 3-kinase, 10 M LY294002, and 1 M wortmannin ( Fig.  4C , supplementary Fig. 2 ). Inhibiting ERK activation or protein kinase C with 20 M PD98059 or 10 M Gö6983, respectively, had no signifi cant effect on LPA-or S1P-induced decreases in ATX mRNA (results not shown).
We also determined whether the secretion of ATX by SW-579 thyroid cancer cells and MDA-MB-435S melanoma cells would establish a negative feedback regulatory loop on further ATX production. Cells were incubated in medium with delipidated serum to maximize the concentrations of mRNA for ATX and treated with 100 M LPC. This decreased ATX mRNA concentrations, an effect that was reversed by inhibiting ATX activity with either ONO-8430506 or S32826 ( Fig. 5A , supplementary Fig. 3) . As controls, we demonstrated that these inhibitors had no significant effects on ATX mRNA when added in the absence of LPC, or in the presence of LPA ( Secreted ATX protein was quantifi ed by ELISA and normalized to both volume of conditioned medium and cell lysate protein content. ATX protein from basal medium was subtracted from the total ATX protein measured after incubation. Results are mean ± SEM from three independent experiments. *A signifi cant increase ( P < 0.05) in ATX protein concentration in FBSC medium compared with FBS medium. #A signifi cant decrease ( P < 0.05) in ATX protein following LPA or S1P treatment in FBSC compared with FBSC alone. increases ATX secretion by adipose tissue resulting in more ATX in the plasma.
Both ATX and LPA levels increase in infl ammatory conditions such as cancer
We also investigated the relationship between ATX and LPA levels in infl ammatory conditions such as cancer. Consistent with previous results ( 9 ), Balb/c mice with 4T1 breast tumors at day 21 have signifi cantly elevated plasma ATX levels ( Fig. 7A ). These mice also have nearly twice the plasma LPA concentrations of control mice without cancer ( Fig. 7B ) . S1P concentrations were not affected ( Fig. 7C ) . The mice also have nearly 40 times higher plasma levels of the pro-infl ammatory cytokine, TNF-␣ ( Fig. 7C ) . From these observations, we proposed that infl ammatory cytokines counteract the inhibition of ATX mRNA expression by LPA and S1P. Stimulation of SW-579 cells with TNF-␣ or IL-1 ␤ alone or in combination increased ATX mRNA concentrations. TNF-␣ or IL-1 ␤ also overcame the inhibition on ATX mRNA expression by either 1 M LPA or S1P ( Fig. 7D ) .
DISCUSSION
We concluded from our results that the product inhibition of ATX by LPA and S1P is an artifact of the FS-3 supplementary Fig. 3 ). The suppression of mRNA concentrations for ATX by LPA and LPC were paralleled by decreased secretion of ATX from the cells ( Fig. 5B ) . Inhibiting ATX activity with ONO-8430506 or S32826 reversed these effects of LPC.
Inhibition of ATX in vivo increases adipose tissue ATX expression and plasma ATX concentrations
The role of ATX in regulating its own expression was also investigated in vivo by treating mice for 4 days with 100 mg/kg ONO-8430506. This inhibitor decreased the activity of ATX as measured in the plasma using 3 mM C18:1-LPC ( 9 ) by about 95% and this was accompanied by a decrease of about 80% in measured LPA molecular species concentrations ( Fig. 6A, B ) . S1P concentrations were not affected by ONO-8430506 ( Fig. 6B ) , as expected from previous work ( 9 ) . Adipose tissue is a major source of ATX in the circulation (37) (38) (39) (40) , and therefore, we measured the expression of ATX mRNA in the mammary fat pads of the female mice. ATX mRNA was increased by about 5.5-fold in the ONO-8430506-treated mice and this was accompanied by 3-fold increase in the concentration of ATX protein in the plasma ( Fig. 6C-E ) . We conclude from these results that the expression and secretion of ATX from adipose tissue is suppressed by plasma LPA concentrations. Conversely, decreasing plasma LPA concentrations FBS has been used as a source of ATX to test the effi cacy of novel ATX inhibitors in the FS-3 assay ( 45, 46 ) , but our work now shows this assay detects little true ATX activity unless lysophospholipids are removed from the serum. Similar problems are likely to occur if fl uorescent probes are used to measured ATX activity in concentrated conditioned medium from cell culture ( 32, 47, 48 ) . This can result from the production of lysophospholipids by the cells or the addition of FBS to the medium. We demonstrate that the presence of very low concentrations of serum can inhibit the assays because low micromolar concentrations of LPC, LPA, and S1P can significantly assay and that it is unlikely to have physiological relevance. This conclusion also has implications for identifying ATX inhibitors because low concentrations of fl uorescent probes are often used to screen libraries of compounds or test the effi cacy of derivatives (41) (42) (43) . While these probes may be effi cient for screening potential compounds, positive hits for ATX inhibition or derivative analogs should be verifi ed in the presence of physiological concentrations of LPC, as used in the choline release assay. Physiologically relevant LPC concentrations have been used to validate the in vitro effi cacy of many such inhibitors ( 15, 20, 21, 29, 44 ) . delipidated serum. We recommend that future studies on the role of LPA or S1P in regulating ATX mRNA expression should be performed in delipidated serum using signifi cantly longer time scales.
Inhibition of ATX activity in vivo, and the consequent decrease in LPA, increased ATX production in adipose tissue resulting in a higher concentration of ATX protein in the plasma. However, the ATX inhibitor, ONO-8430506, keeps this ATX catalytically inactive, as verifi ed by the marked decrease in LPA concentrations. This highly potent and selective ATX (ENPP2) inhibitor does not inhibit the activity of other ENPP family members or affect ligand binding to sixty tested pharmacological drug targets ( 29 ) . The mechanism by which ATX would normally regulate its own secretion by increasing LPA concentrations is typical of a physiological feedback loop. It is, therefore, fully expected that a potent ATX inhibitor would increase ATX expression. In fact, such an increase can serve as a surrogate measure of the effectiveness of the inhibitor. In this feedback model, S1P concentrations were not changed by ATX inhibition. This fi nding is not surprising as ATX (+/ Ϫ ) mice have half the levels of plasma LPA compared with normal mice, but S1P levels are not affected ( 3, 54 ) . This means that ATX is not a major regulator of S1P concentrations in vivo. However, our animal studies do not exclude S1P as being a physiological regulator of ATX inhibit ATX activity as measured with fl uorescent substrates. Therefore, if serum has to be used in these cultures to maintain cell viability, it should be delipidated.
We also conclude from our work that activation of phosphatidylinositol 3-kinase through LPA 1 and S1P 1 receptors decreases the expression of mRNA for ATX. LPA generated from LPC by ATX, therefore, acts as a feedback suppressor of ATX mRNA production. This feedback effect can be blocked in vivo by inhibiting ATX activity and lowering LPA concentrations. The latter work demonstrates the physiological importance of the secreted ATX producing LPA from LPC in this feedback regulation. To our knowledge, no other studies have looked directly at LPA and S1P effects on ATX expression. ATX mRNA expression levels were not signifi cantly changed in other cell types treated with LPA or S1P, as determined by gene arrays on cancer cells, smooth muscle cells, mouse embryonic fi broblasts, and human embryonic stem cells (49) (50) (51) (52) (53) . However, some of these studies look at cells cultured in 10-20% FBS and all these studies were performed after р 6 h LPA or S1P treatment. Our results show that the amount of LPA and S1P present in 10% FBS is suffi cient to significantly suppress ATX mRNA expression, and the addition of more LPA or S1P is unlikely to cause a further suppression. Also, we observed maximum effects of LPA or S1P on ATX mRNA expression at 24 h in cells cultured in that does not heal" (56) (57) (58) . Breaking the infl ammatory cycle with an ATX inhibitor decreases the production of both LPA and infl ammatory cytokines, which decreases tumor progression, metastasis and the production of chemoresistance ( 1, 2, 9, 12 ) . This occurs even though ATX production is increased because the ATX remains catalytically inactive. expression in vivo, and further studies are warranted. We also demonstrated that the effects of removing LPA from serum are readily reversible and that increasing LPA concentrations decreased the elevated ATX expression.
This work also provides novel evidence concerning the regulation of ATX expression during wound healing, infl ammation, and cancer. We detected signifi cant increases in both plasma ATX activity and LPA concentrations in Balb/c mice with advanced 4T1 breast tumors together with increased plasma TNF-␣ levels. We established that addition of the pro-infl ammatory cytokines, TNF-␣ and/ or IL-1 ␤ , overcome LPA-mediated suppression of ATX expression. We also demonstrate in unpublished observations that ATX expression can be increased to similar levels by 10 other infl ammatory chemokines and cytokines. These results indicate that cytokine signaling is extremely redundant with respect to the regulation of ATX expression and that loss of an individual cytokine is unlikely to produce a signifi cant effect.
Our results from cell culture are compatible with the conclusion that the production of infl ammatory cytokines, such as TNF-␣ and IL-1 ␤ , in damaged and infl amed tissue is a signal for increased ATX expression and the need for LPA production to heal the wound ( 1, 55 ) . If this process is successful and infl ammation subsides, then LPA produced by ATX feeds back and blocks further ATX production. However, if infl ammation is unresolved, then TNF-␣ and IL-1 ␤ stimulate further ATX production and the consequent formation of LPA stimulates further cytokine production in a vicious cycle ( 1 ) . This situation particularly applies to cancer, which is often described "as a wound Fig. 7 . Mice with cancer have higher plasma ATX activity, LPA concentrations, and TNF-␣ concentrations, and pro-infl ammatory cytokines can overcome LPA-and S1P-mediated inhibition of ATX mRNA expression. Female Balb/c mice were either sham injected (No Cancer) or injected with 20,000 4T1 Balb/c breast cancer cells (Cancer) and plasma was collected 21 days later. Plasma ATX activity (A), plasma concentrations of LPA (sum of C16:0, C18:0, C18:1, and C20:4 molecular species) and S1P levels (B), and plasma TNF-␣ compared with mice with no cancer (C). *A signifi cant increase in mice with cancer compared with mice without cancer (n = 5-8 mice per group). D: SW-579 cells were incubated in 10% FBSC for 24 h in the presence of 1 M LPA or S1P and 10 ng/ml of the pro-infl ammatory cytokines TNF-␣ and/or IL-␤ , as indicated. Results are mean ± SEM from three independent experiments. *A signifi cant increase in ATX mRNA for cells treated with cytokines compared with no treatment; #LPA and S1P signifi cantly suppress ATX mRNA expression compared with no treatment; **a signifi cant increase in ATX mRNA for cells treated with both LPA and cytokines compared with LPA treatment alone; ##a signifi cant increase in ATX mRNA for cells treated with both S1P and cytokines compared with S1P treatment alone. Supplemental Material can be found at:
